@article{BohlkenWeberSiebertetal.2017,
  author    = {Bohlken, Jens and Weber, Simon A. and Siebert, Anke and Forstmeier, Simon and Kohlmann, Thomas and Rapp, Michael A.},
  title     = {Reminiscence therapy for depression in dementia},
  series = {GeroPsych - The Journal of gerontopsychology and geriatric psychiatry},
  volume    = {30},
  journal   = {GeroPsych - The Journal of gerontopsychology and geriatric psychiatry},
  publisher = {Hogrefe},
  address   = {G{\"o}ttingen},
  issn      = {1662-9647},
  doi       = {10.1024/1662-9647/a000175},
  pages     = {145 -- 151},
  year      = {2017},
  abstract  = {We investigated the efficacy of reminiscence therapy (RT) on symptoms of depression in patients with mild to moderate dementia. Out of 227 patients with mild to moderate dementia from a specialized physician's office, 27 pairs (N = 54; mean age 79.04 ± 6.16 years) who had either received treatment as usual (TAU) or TAU combined with RT, were matched retrospectively according to age as well as cognitive and depressive symptom scores. After controlling for age and sex, symptoms of depression significantly decreased over time in the RT group compared to TAU (F1,52 = 4.36; p < .05). RT is a promising option for the treatment of depression in mild to moderate dementia. Larger randomized-controlled trials are needed.},
  language  = {en}
}
@book{MientusKlempinNowaketal.2023,
  author    = {Mientus, Lukas and Klempin, Christiane and Nowak, Anna and Wyss, Corinne and Aufschnaiter, Claudia von and Faix, Ann-Christin and te Poel, Kathrin and Wahbe, Nadia and Pieper, Martin and H{\"o}ller, Katharina and Kallenbach, Lea and F{\"o}rster, Magdalena and Redecker, Anke and Dick, Mirjam and Holle, J{\"o}rg and Schneider, Edina and Rehfeldt, Daniel and Brauns, Sarah and Abels, Simone and Ferencik-Lehmkuhl, Daria and Fr{\"a}nkel, Silvia and Frohn, Julia and Liebsch, Ann-Catherine and Pech, Detlef and Schreier, Pascal and Jessen, Moiken and Großmann, Uta and Skintey, Lesya and Voerkel, Paul and Vaz Ferreira, Mergenfel A. and Zimmermann, Jan-Simon and Buddeberg, Magdalena and Henke, Vanessa and Hornberg, Sabine and V{\"o}lschow, Yvette and Warrelmann, Julia-Nadine and Malek, Jennifer and Tinnefeld, Anja and Schmidt, Peggy and Bauer, Tobias and J{\"a}nisch, Christopher and Spitzer, Lisa and Franken, Nadine and Degeling, Maria and Preisfeld, Angelika and Meier, Jana and K{\"u}th, Simon and Scholl, Daniel and Vogelsang, Christoph and Watson, Christina and Weißbach, Anna and Kulgemeyer, Christoph and Oetken, Mandy and Gorski, Sebastian and Kubsch, Marcus and Sorge, Stefan and Wulff, Peter and Fellenz, Carolin D. and Schnell, Susanne and Larisch, Cathleen and Kaiser, Franz and Knott, Christina and Reimer, Stefanie and Stegm{\"u}ller, Nathalie and Boukray{\^a}a Trabelsi, Kathrin and Schißlbauer, Franziska and Lemberger, Lukas and Barth, Ulrike and Wiehl, Angelika and Rogge, Tim and B{\"o}hnke, Anja and Dietz, Dennis and Großmann, Leroy and Wienmeister, Annett and Zoppke, Till and Jiang, Lisa and Gr{\"u}nbauer, Stephanie and Ostersehlt, D{\"o}rte and Peukert, Sophia and Sch{\"a}fer, Christoph and L{\"o}big, Anna and Br{\"o}ll, Leena and Brandt, Birgit and Breuer, Meike and Dausend, Henriette and Krelle, Michael and Andersen, Gesine and Falke, Sascha and Kindermann-G{\"u}zel, Kristin and K{\"o}rner, Katrina and Lottermoser, Lisa-Marie and P{\"u}gner, Kati and Sonnenburg, Nadine and Akarsu, Selim and Rechl, Friederike and Gadinger, Laureen and Heinze, Lena and Wittmann, Eveline and Franke, Manuela and Lachmund, Anne-Marie and B{\"o}ttger, Julia and Hannover, Bettina and Behrendt, Renata and Conty, Valentina and Grundmann, Stephanie and Ghassemi, Novid and Opitz, Ben and Br{\"a}mer, Martin and Gasparjan, David and Sambanis, Michaela and K{\"o}ster, Hilde and L{\"u}cke, Martin and Nordmeier, Volkhard and Schaal, Sonja and Haberbosch, Maximilian and Meissner, Maren and Schaal, Steffen and Br{\"u}chner, Melanie and Riehle, Tamara and Leopold, Bengta Marie and Gerlach, Susanne and Rau-Patschke, Sarah and Skorsetz, Nina and Weber, Nadine and Damk{\"o}hler, Jens and Elsholz, Markus and Trefzger, Thomas and Lewek, Tobias and Borowski, Andreas},
  title     = {Reflexion in der Lehrkr{\"a}ftebildung},
  series = {Potsdamer Beitr{\"a}ge f{\"u}r Lehrkr{\"a}ftebildung und Bildungsforschung},
  journal   = {Potsdamer Beitr{\"a}ge f{\"u}r Lehrkr{\"a}ftebildung und Bildungsforschung},
  number    = {4},
  editor    = {Mientus, Lukas and Klempin, Christiane and Nowak, Anna},
  publisher = {Universit{\"a}tsverlag Potsdam},
  address   = {Potsdam},
  isbn      = {978-3-86956-566-8},
  issn      = {2626-3556},
  doi       = {10.25932/publishup-59171},
  url       = {http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-591717},
  publisher      = {Universit{\"a}t Potsdam},
  pages     = {452},
  year      = {2023},
  abstract  = {Reflexion ist eine Schl{\"u}sselkategorie f{\"u}r die professionelle Entwicklung von Lehrkr{\"a}ften, welche als Ausbildungsziel in den Bildungsstandards f{\"u}r die Lehrkr{\"a}ftebildung verankert ist. Eine Verstetigung universit{\"a}r gepr{\"a}gter Forschung und Modellierung in der praxisnahen Anwendung im schulischen Kontext bietet Potentiale nachhaltiger Professionalisierung. Die St{\"a}rkung reflexionsbezogener Kompetenzen durch Empirie und Anwendung scheint eine phasen{\"u}bergreifende Herausforderung der Lehrkr{\"a}ftebildung zu sein, die es zu bew{\"a}ltigen gilt. Ziele des Tagungsbandes Reflexion in der Lehrkr{\"a}ftebildung sind eine theoretische Sch{\"a}rfung des Konzeptes „Reflexive Professionalisierung" und der Austausch {\"u}ber Fragen der Einbettung wirksamer reflexionsbezogener Lerngelegenheiten in die Lehrkr{\"a}ftebildung. Forschende und Lehrende der‚ drei Phasen (Studium, Referendariat sowie Fort- und Weiterbildung) der Lehrkr{\"a}ftebildung stellen Lehrkonzepte und Forschungsprojekte zum Thema Reflexion in der Lehrkr{\"a}ftebildung vor und diskutieren diese. Gemeinsam mit Teilnehmenden aller Phasen und von verschiedenen Standorten der Lehrkr{\"a}ftebildung werden zuk{\"u}nftige Herausforderungen identifiziert und L{\"o}sungsans{\"a}tze herausgearbeitet.},
  language  = {de}
}
@misc{BohlkenWeberRappetal.2015,
  author    = {Bohlken, Jens and Weber, Simon and Rapp, Michael A. and Kostev, Karel},
  title     = {Continuous treatment with antidementia drugs in Germany 2003-2013},
  series = {Postprints der Universit{\"a}t Potsdam : Humanwissenschaftliche Reihe},
  journal   = {Postprints der Universit{\"a}t Potsdam : Humanwissenschaftliche Reihe},
  number    = {522},
  issn      = {1866-8364},
  doi       = {10.25932/publishup-41471},
  url       = {http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-414718},
  pages     = {8},
  year      = {2015},
  abstract  = {Background: Continuous treatment is an important indicator of medication adherence in dementia. However, long-term studies in larger clinical settings are lacking, and little is known about moderating effects of patient and service characteristics. Methods: Data from 12,910 outpatients with dementia (mean age 79.2 years; SD = 7.6 years) treated between January 2003 and December 2013 in Germany were included. Continuous treatment was analysed using Kaplan-Meier curves and log-rank tests. In addition, multivariate Cox regression models were fitted with continuous treatment as dependent variable and the predictors antidementia agent, age, gender, medical comorbidities, physician specialty, and health insurance status. Results: After one year of follow-up, nearly 60\% of patients continued drug treatment. Donezepil (HR: 0.88; 95\% CI: 0.82-0.95) and memantine (HR: 0.85; 0.79-0.91) patients were less likely to be discontinued treatment as compared to rivastigmine users. Patients were less likely to be discontinued if they were treated by specialist physicians as compared to general practitioners (HR: 0.44; 0.41-0.48). Younger male patients and patients who had private health insurance had a lower discontinuation risk. Regarding comorbidity, patients were more likely to be continuously treated with the index substance if a diagnosis of heart failure or hypertension had been diagnosed at baseline. Conclusions: Our results imply that besides type of antidementia agent, involvement of a specialist in the complex process of prescribing antidementia drugs can provide meaningful benefits to patients, in terms of more disease-specific and continuous treatment.},
  language  = {en}
}
@article{BohlkenWeberRappetal.2015,
  author    = {Bohlken, Jens and Weber, Simon and Rapp, Michael A. and Kostev, Karel},
  title     = {Continuous treatment with antidementia drugs in Germany 2003-2013: a retrospective database analysis},
  series = {International psychogeriatrics},
  volume    = {27},
  journal   = {International psychogeriatrics},
  number    = {8},
  publisher = {Cambridge Univ. Press},
  address   = {New York},
  issn      = {1041-6102},
  doi       = {10.1017/S1041610215000654},
  pages     = {1335 -- 1342},
  year      = {2015},
  abstract  = {Background: Continuous treatment is an important indicator of medication adherence in dementia. However, long-term studies in larger clinical settings are lacking, and little is known about moderating effects of patient and service characteristics. Methods: Data from 12,910 outpatients with dementia (mean age 79.2 years; SD = 7.6 years) treated between January 2003 and December 2013 in Germany were included. Continuous treatment was analysed using Kaplan-Meier curves and log-rank tests. In addition, multivariate Cox regression models were fitted with continuous treatment as dependent variable and the predictors antidementia agent, age, gender, medical comorbidities, physician specialty, and health insurance status. Results: After one year of follow-up, nearly 60\% of patients continued drug treatment. Donezepil (HR: 0.88; 95\% CI: 0.82-0.95) and memantine (HR: 0.85; 0.79-0.91) patients were less likely to be discontinued treatment as compared to rivastigmine users. Patients were less likely to be discontinued if they were treated by specialist physicians as compared to general practitioners (HR: 0.44; 0.41-0.48). Younger male patients and patients who had private health insurance had a lower discontinuation risk. Regarding comorbidity, patients were more likely to be continuously treated with the index substance if a diagnosis of heart failure or hypertension had been diagnosed at baseline. Conclusions: Our results imply that besides type of antidementia agent, involvement of a specialist in the complex process of prescribing antidementia drugs can provide meaningful benefits to patients, in terms of more disease-specific and continuous treatment.},
  language  = {en}
}